MAP2K1 and posterior cortical atrophy: Preclinical studies involving tuvusertib have been focused on the ATRi’s direct cytotoxicity and have demonstrated its synergy with other DNA-targeted agents and MEK1/2 inhibitors [4, 30] We report for the first time that a sublethal dose of tuvusertib can act as an immunogenic modulator that reprograms PCa cells to become more susceptible to subsequent immunotherapy.